transcriptomics
Mammogen Closes $2M Seed Round Supporting GenTRU Liquid Biopsy Tech for Breast Cancer Detection
The funds will help support the firm's clinical development of a blood-based transcriptomic assay for the screening and detection of breast cancer.
Aiming to Cut Unnecessary Surgeries, City of Hope Team to Commercialize CRC Metastasis Dx Signature
Premium
The team will use the reverse-transcriptase quantitative PCR test, which uses a milliliter of a patient's blood, to curb unneeded radical colon cancer surgeries.
Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.
Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit
Premium
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
Tempus Gets CE Mark for xT Tumor Sequencing Assay
The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.